80 results about "Antibody affinity" patented technology

The invention discloses a hydrophilic magnetic graphene material for fixing an FcRn receptor and a synthesis method, and relates to the technical field of biological materials, the method comprises the following steps: preparing graphene oxide; synthesizing Fe3O4 microspheres on the surface of the graphene oxide to obtain magnetic graphene; coating the surface of the magnetic graphene with a polydopamine layer; grafting a PAMAM (Polyamidoamine) dendritic macromolecule; and fixing the FcRn receptor to obtain the hydrophilic magnetic graphene material for fixing the FcRn receptor. The method has the advantages of large specific surface area, high protein immobilization amount and excellent extraction efficiency, and can accurately reflect the dynamic characteristics of strict pH dependent binding and dissociation of the antibody and FcRn, thereby solving the problems that the existing antibody-FcRn affinity analysis method cannot truly reflect the in-vivo dynamic characteristics and the material extraction efficiency is low.

The invention discloses an addiction-related epitope intelligent prediction and antibody optimization design method, and belongs to the field of medicine.The design method specifically comprises the following steps that firstly, multi-source heterogeneous biological information data are integrated, and the potential space structure, dynamic stability and regulation and control characteristics of an epitope are extracted; iI, identifying a low-immunogenicity region in the addiction target, and generating a high-adaptability candidate epitope according to the identified low-immunogenicity region; iII, optimizing antibody design according to the high-adaptability candidate epitopes, and dynamically adjusting the antibody design according to real-time molecular dynamics simulation feedback; according to the method, double optimization of antibody affinity and safety can be realized, the design efficiency and accuracy are improved, the problems of blind screening and low-efficiency verification in a traditional method are avoided, and the recognition redundancy of the antibody is improved, so that the effective period of a drug is prolonged, and the off-target risk is reduced.

The invention discloses an anti-human MerTK antibody and an application of the anti-human MerTK antibody. The anti-human MerTK antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody disclosed by the invention is high in affinity, can specifically inhibit the interaction of the ligand Gas6-MerTK and the ligand protein S-MerTK at the same time, and does not inhibit the interaction of the ligand Tulp1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

The application relates to the technical field of artificial intelligence, in particular to an antigen-antibody affinity prediction method, system and device, which comprises the following steps: performing feature extraction on amino acid sequence data of an antigen and an antibody, and generating a preliminary complex three-dimensional conformation through a prediction model; fusing and screening a plurality of preliminary complex three-dimensional conformations to determine an intermediate complex three-dimensional conformation; optimizing a binding interface of the intermediate complex three-dimensional conformation based on molecular dynamics simulation and a reinforcement learning algorithm to obtain a final optimized conformation; performing energy decomposition based on a molecular force field principle to obtain key energy parameters, and obtaining a binding free energy through an affinity prediction deep neural network based on the key energy parameters and energy characteristics determined by the molecular dynamics simulation; and when the binding free energy is higher than a judgment threshold, re-performing optimization and determining the binding free energy. In this way, the accuracy and reliability of prediction can be significantly improved on the basis of realizing full-process automation.

The present invention discloses an anti-programmed death receptor 1 antibody H1 and its application. The amino acid sequences of the CDR1, CDR2, and CDR3 of the heavy chain of the anti-programmed death receptor 1 antibody H1 include the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The present invention uses PD-1 protein to immunize alpacas. The anti-programmed death receptor 1 antibody H1 obtained has strong affinity and can block the binding of PD-1 and PD-L1, enhance the function of immune cells, and improve the ability of T cells to eliminate tumors.

The invention relates to the technical field of immunology and biology, in particular to a light chain variable region and a heavy chain variable region of a rabbit anti-canine CD3E monoclonal antibody and application of the light chain variable region and the heavy chain variable region. The rabbit anticanine CD3E monoclonal antibody is successfully developed, and the antibody can be applied to experiments such as ELISA (enzyme-linked immunosorbent assay), flow cytometry, immunohistochemistry, stimulation of canine T cell activation and the like. Meanwhile, after being transfected to the surface of a tumor cell, the T cell can be promoted to kill the tumor. The development of the antibody provides a basic tool for detection and subsequent tumor immunotherapy. Meanwhile, the problems of low affinity, poor antigen specificity and the like of a traditional antibody are solved, the performance of the antibody is improved, and the application scene of the antibody is expanded.

The invention relates to the technical field of biology, in particular to a method for improving affinity of a nano antibody based on computer-aided design. According to the method, a series of bioinformatics tools for nano antibody affinity maturation are investigated and researched in literatures, and part of databases, servers and software are optimized to construct a set of computer-aided design (CAD) nano antibody affinity improvement method by evaluating the operability and the improvement effect of the tools. In order to verify the effectiveness and universality of the method, based on the method, a high-affinity mutant nano antibody is virtually screened out of an Anti-Nectin-4 camel source nano antibody NBNT-1 and an Anti-PD-L1 shark source nano antibody NBNT4 screened in a synthetic library through model construction, model evaluation, site prediction, molecular docking, structural analysis, mutation prediction and mutation evaluation. Traditional in-vitro affinity maturation methods, such as error-prone PCR, are low in screening efficiency, large in randomness introduced by mutation, long in experimental period, large in workload and difficult to accurately optimize the affinity of target molecules. According to the method, various defects of a traditional in-vitro affinity maturation method are overcome, and the success rate and efficiency of affinity maturation are improved.

The invention provides an anti-CD13 Raja sinensis nano antibody and application thereof. In a complementary determining region of the antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 1, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The antibody is soluble in water, has activity and can be used for BLI determination of antigen-antibody affinity, the development period and cost of the antibody are remarkably reduced, and the superiority of the Chinese rhodiola rosea source VNAR sequence in the aspect of hydrophilicity is indicated; the KD value of the CD13 antigen and one antibody is measured to be 159.3 nM and is at the medium level of the affinity of the natural VNAR antibody; a molecular tool is provided for developing a novel CD13 inhibitor, and the clinical transformation problem of the inhibitor is expected to be solved.

The invention belongs to the field of nano antibodies, and relates to an NKG2A antibody or an antigen-binding part thereof and application of the NKG2A antibody or the antigen-binding part thereof. The NKG2A antibody or an antigen binding part of the NKG2A antibody is composed of a heavy chain variable structural domain, and the amino acid sequence of a heavy chain CDR1 is X1YTSX2TNFF (SEQ ID NO: 39); the amino acid sequence of the heavy chain CDR2 is ISX3TGX4YT (SEQ ID NO: 40); and the amino acid sequence of the heavy chain CDR3 is AAGX5RX6GDNWEX7EX8SWFY (SEQ ID NO: 41). Compared with the prior art, the invention has the beneficial effects that the NKG2A antibody or the antigen binding part thereof is screened by using a biological genetic engineering technology, and the affinity of the antibody is better.

The invention provides a cTnI protein antibody. The cTnI protein antibody comprises an anti-human cTnI protein monoclonal antibody I, an anti-human cTnI protein monoclonal antibody II and / or an anti-human cTnI protein monoclonal antibody III, the antibody respectively comprises a light chain and a heavy chain; wherein the light chain sequence of the antibody I is as shown in SEQ ID NO.1, and the heavy chain sequence of the antibody I is as shown in SEQ ID NO.2; a light chain sequence of the antibody II is as shown in SEQ ID NO.3, and a heavy chain sequence of the antibody II is as shown in SEQ ID NO.4; the light chain sequence of the antibody III is as shown in SEQ ID NO.5, and the heavy chain sequence of the antibody III is as shown in SEQ ID NO.6. The invention also provides a latex enhanced immunoturbidimetric kit for quantitatively detecting the cTnI protein and a preparation method of the latex enhanced immunoturbidimetric kit. The invention has the advantages that the antibody affinity is high, the specificity is good, and a kit based on the antibody is high in sensitivity, good in specificity and strong in anti-interference capability.

The invention discloses an anti-MerTK antibody and an application of the anti-MerTK antibody. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody provided by the invention has high affinity, and can simultaneously block the interaction of the ligand GAS6-MerTK and the ligand protein S-MerTK, but does not block the interaction of the ligand TULP1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

The present application relates to a model for predicting high-affinity mutation sites of antibodies and a construction method and application thereof. The construction method comprises: taking the amino acid sequence of a mutant antibody with improved affinity as a training set, the training set comprising the amino acid sequence of the mutant antibody, the mutation site and the amino acid information after mutation, taking the amino acid after mutation as the correct prediction target, training the ESM model using the training set, the training comprising masking the amino acid sequence of the mutation site of the mutant antibody using a masking language model, then predicting the amino acid sequence of the masking site, outputting the probability of the correct prediction target, adjusting the model according to the output result, and obtaining the model for predicting high-affinity mutation sites of antibodies. The present application optimizes the construction of the model for predicting high-affinity mutation sites of antibodies based on the ESM model training, and can be effectively applied to antibody affinity maturation technology to predict effective mutation site combinations.

This invention relates to a detection kit and preparation method for enhancing the detection efficacy of autoimmune encephalitis (CBA) antibodies. The kit comprises genetically engineered 293T cells stably integrating and co-expressing the eIF2α S52A mutant and HSP70, and transiently transfected with CBA-associated antigens. The preparation method includes constructing a co-expression vector, establishing a stable transfection cell line, stress preconditioning treatment, antigen transfection, and kit assembly. A method for assessing antibody affinity maturation using this kit is also provided. By synergistically modifying detection cells at three levels—translational regulation, protein folding, and anti-apoptosis—the invention significantly increases antigen expression, reduces apoptosis, and improves detection sensitivity and specificity. Furthermore, it integrates antibody affinity assessment into CBA detection for the first time, providing auxiliary information for clinical staging.

The invention discloses an MTBR-tau243 specific antibody and application of the MTBR-tau243 specific antibody in an Alzheimer's disease auxiliary diagnosis kit, belongs to the technical field of immunoassay, and provides an MTBR-tau243 targeted antibody and a chemiluminescence kit for detecting MTBR-tau243. The antibody is high in affinity, high in sensitivity and obviously shortened in production cycle, and is more suitable for being used as a core raw material to be applied to the field of in-vitro diagnostic reagents. The kit disclosed by the invention can be used for auxiliary diagnosis of diseases related to MTBR-tau243, such as Alzheimer's disease.

The present application relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is a protein expressed on the surface of regulatory T cells. The binding molecule provided by the present application can inhibit the function of regulatory T cells, thereby effectively preventing, improving or treating cancer, especially solid tumors. In addition, compared with commercially available antibodies against Lrig-1, the binding molecule provided by the present application can more effectively target Lrig-1 protein and show excellent binding affinity.

The invention relates to the technical field of artificial intelligence, in particular to an antigen-antibody affinity prediction method, system and equipment, and the method comprises the following steps: carrying out feature extraction on amino acid sequence data of an antigen and an antibody, and generating a preliminary compound three-dimensional conformation through a prediction model; fusing and screening the plurality of preliminary compound three-dimensional conformations, and determining an intermediate compound three-dimensional conformation; on the basis of molecular dynamics simulation and reinforcement learning algorithms, optimizing a binding interface of the three-dimensional conformation of the intermediate compound to obtain a final optimized conformation; performing energy decomposition on the basis of a molecular force field principle to obtain key energy parameters, and predicting a deep neural network through affinity on the basis of the key energy parameters and energy characteristics determined by molecular dynamics simulation to obtain combined free energy; and when the combined free energy is higher than the judgment threshold value, optimization is carried out again, and the combined free energy is determined. Therefore, on the basis of realizing full-process automation, the accuracy and reliability of prediction can be obviously improved.

This application discloses a method for screening single B cells. The method provided in this application uses magnetic beads coated with IL-6 antigen, combined with fluorescently labeled secondary antibody, and employs droplet microfluidic technology to rapidly sort B cells. The obtained IL-6 positive B cells are then directly cultured, and the generated antibodies are subjected to ELISA and IL-6 antigen-antibody affinity detection to obtain the target cell line. The entire process is greatly simplified and the workload is significantly reduced.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and / or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

The invention relates to a trace hydroxyputrescine lysine protein detection method, which comprises: 1) preparing a sample to be detected, and slicing cells, body fluid or tissue; (2) sealing the sample by using Duolink sealing liquid; (3) diluting an anti-rabbit PLUS probe and an anti-mouse MINUS probe Merck and DUO92101 / DUO92102 in proportion by using a Duolinkantibody diluent, incubating with a product obtained in the previous step, and respectively combining a rabbit polyclonal antibody and a mouse monoclonal antibody through the PLUS / MINUS probe to provide a basis for a ligation reaction; (4) diluting ligase by using a Duolink ligation buffer solution according to the ratio, and incubating with the product in the step (3) at the temperature; 5) diluting an amplification enzyme with a Duolink amplification buffer solution in proportion, and incubating with a product obtained in the previous step; 6, a mounting medium containing DAPI is adopted for mounting, and imaging analysis is carried out through a fluorescence or confocal microscopy. The problem that due to the fact that the affinity of the antibody is insufficient and the protein expression quantity is low, the omission ratio of the trace hydroxyputrescine lysine modified protein is high can be well solved.

The invention relates to an AVRcap1b nano antibody and application thereof, and belongs to the field of biological medicines.The anti-AVRcap1b nano antibody is developed through multiple steps of detection, screening and the like by adopting a yeast two-hybrid screening system, the whole screening cost is greatly reduced compared with that of a traditional antibody, the research and development period is short, the requirements for the experimental environment and equipment are simple, and the applicability is wide. Compared with a traditional AVRcap1b antibody, the developed AVRcap1b nano antibody has the advantages that the molecular weight is smaller, the tissue permeability is better, meanwhile, the nano antibody is more stable, and the immunogenicity is low. In a word, the AVRcap1b nano antibody has outstanding advantages in the aspects of antibody affinity, targeting specificity, small molecule size, stability, modifiability, production cost and the like.

The invention provides an antigen-antibody affinity prediction method of a cross-modal fusion composite structure and sequence, and belongs to the technical field of natural language processing. Firstly, a data set of antigen-antibody affinity is obtained and divided into a training set, a verification set and a test set; secondly, constructing an antibody and antigen sequence information mining module; then constructing an antibody and antigen complex structure information mining module; secondly, inputting the multi-scale feature representation of the antibody and the antigen into a fusion layer to generate a steady affinity prediction result; and finally, comparing a predicted value with a true value, training the best parameter of the model, and storing the best parameter. Through multi-modal and multi-scale information extraction and cross-modal fusion, information interaction between two modals of the antigen and antibody sequence set structure is realized, and the precision and robustness of affinity prediction are improved.

The invention relates to an anti-CD33 single-domain antibody and application thereof. According to the invention, the anti-CD33 single-domain antibody specifically bound with CD33 is screened by using a biological gene engineering technology, and the antibody has good affinity and is used for treating hematological malignant tumors and other CD33 related diseases.

The invention belongs to the field of immunology, and relates to an anti-CEACAM7 single-domain antibody and application thereof. The single-domain antibody is composed of heavy chains, and the heavy chains comprise a heavy chain CDR1 as shown in any one of SEQ ID NO: 19 to SEQ ID NO: 22, a heavy chain CDR2 as shown in any one of SEQ ID NO: 23 to SEQ ID NO: 26 and a heavy chain CDR3 as shown in any one of SEQ ID NO: 27 to SEQ ID NO: 29. Compared with the prior art, the invention has the beneficial effects that the single-domain antibody specifically aiming at CEACAM7 is screened by using a biological genetic engineering technology, and the affinity of the antibody is better.

The application relates to the fields of biological medicine and antibody engineering technology, and particularly relates to a STAT3 hybridoma-derived antibody affinity maturation method based on computational biology, which comprises the following steps: (1) obtaining an antibody variable region sequence; (2) constructing STAT3 antigen and antibody models and evaluating; (3) performing antigen-antibody molecular docking and optimization, and screening out models; (4) performing docking model analysis, and obtaining potential saturation mutation sites; (5) performing site saturation mutation, and obtaining mutation results; (6) performing mutation site analysis, and determining final mutation sites; (7) amplifying a target fragment containing the mutation sites; (8) constructing a recombinant expression vector, and obtaining a reformed STAT3 recombinant antibody through eukaryotic expression and purification; and (9) performing relative affinity determination.

The invention relates to an AVRcap1b nano antibody and application thereof, and belongs to the field of biological medicines.The anti-AVRcap1b nano antibody is developed through multiple steps of detection, screening and the like by adopting a yeast two-hybrid screening system, the whole screening cost is greatly reduced compared with that of a traditional antibody, the research and development period is short, the requirements for the experimental environment and equipment are simple, and the applicability is wide. Compared with a traditional AVRcap1b antibody, the developed AVRcap1b nano antibody has the advantages that the molecular weight is smaller, the tissue permeability is better, meanwhile, the nano antibody is more stable, and the immunogenicity is low. In a word, the AVRcap1b nano antibody has outstanding advantages in the aspects of antibody affinity, targeting specificity, small molecule size, stability, modifiability, production cost and the like.

The invention discloses a method for high-throughput determination of antibody affinity based on combination of an antibody chip and surface plasmon resonance imaging. The method comprises the following steps: placing the antibody chip in a surface plasmon resonance imaging instrument, determining and outputting an affinity measurement result; the antibody chip is mainly formed by combining a photo-crosslinking chip and an antibody; the antibody comprises a plurality of antibody molecules, and in the antibody chip, the antibody is combined with the photo-crosslinking chip through chemical bonding. According to the scheme, the affinity value of the antibody combined with the antigen can be obtained on a large scale by circulating the antigen with gradient concentration, and the method for detecting the affinity of the antibody has the advantages of simplicity in operation, accurate detection result, low cost and stable performance.

A compound or a salt thereof comprising: (A) an affinity polypeptide including an affinity moiety having affinity for a heavy chain CH2-CH3 interdomain region of an antibody; (B) a first antibody reactive group; and (C) a second antibody reactive group. The affinity polypeptide includes first and second amino acid residues each having a side chain amino group, and the first antibody reactive group and the second antibody reactive group are linked to the affinity polypeptide via linkers that are introduced into the side chain amino groups of the first and second amino acid residues each having the side chain amino group, respectively.

The invention belongs to the technical field of antigen-antibody affinity prediction, and discloses an antigen-antibody affinity prediction method and device.According to the antigen-antibody affinity prediction method and device, double-position coding is introduced, so that the modeling capacity of dynamic conformation and residue position sensitivity of antibody heavy-chain and light-chain CDR regions is remarkably enhanced, and a model can be used for predicting the antigen-antibody affinity under the condition that the model does not depend on three-dimensional structure data; the sequence diversity characteristics of the CDR region of the antibody can be accurately captured, so that the problem of omission of characterization of a functional region in a traditional sequence method is solved; the cross attention module breaks through the limitation of traditional linear splicing or weighted summation through a heavy chain-light chain-antigen three-way interaction mechanism, and explicitly models the complex interaction among the three. In addition, through hierarchical feature extraction of a deep separable convolution and self-attention hybrid architecture, the model realizes efficient modeling of a long-range dependency relationship.

The invention belongs to the technical field of toxin detection, and particularly relates to a vomitoxin detection method based on a quantum detection technology. Based on a QBs fluorescence labeling technology and a competitive immunochromatography principle, a high-sensitivity quantitative detection system for DON in grain and oil crops is successfully constructed. By systematically optimizing the technical parameters of an antigen-antibody reaction system and a detection device, trace detection of DON (the detection limit reaches 10 ng / mL) is realized. A high-performance monoclonal antibody is screened based on a hybridoma cell technology, indirect ELISA detection shows that the half inhibitory concentration (IC50) to DON is lower than 40 ng / mL, and the affinity advantage of the antibody is verified.